Literature DB >> 12615861

Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.

Gioia S Babini1, Meifang Yuan, Lucinda M C Hall, David M Livermore.   

Abstract

MICs of piperacillin/tazobactam are conventionally determined by varying the concentration of piperacillin in the presence of a fixed 4 mg/L tazobactam. When tested in this way, the MIC distribution for Klebsiella isolates with extended-spectrum beta-lactamases (ESBLs) is strongly bimodal, such that many producers are inhibited at 16 + 4 mg/L whilst others require MICs of > or =512 + 4 mg/L. When, however, piperacillin/tazobactam was tested as a fixed 8:1 ratio, the MIC distribution became unimodal. If clavulanate 4 mg/L was combined with piperacillin, a unimodal MIC distribution was seen for ESBL-producing Klebsiella spp. but a bimodal distribution arose if the clavulanate concentration was reduced to 0.25 mg/L. These data for alternative combinations suggested that the bimodal MIC distribution seen for piperacillin + tazobactam 4 mg/L was a titration effect, not a reflection of some ESBLs being resistant to tazobactam. Even within single strains, as defined by serotype and DNA fingerprints, there was considerable variation in susceptibility to piperacillin + tazobactam 4 mg/L, with some representatives highly susceptible and others highly resistant. Some of the more resistant representatives produced more of their ESBL, or had a greater number of beta-lactamase types, but these associations were not universal. Elevated resistance to piperacillin + tazobactam was not associated with porin change in any ESBL producer examined, but has been found by others.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615861     DOI: 10.1093/jac/dkg114

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Authors:  Oren Zimhony; Inna Chmelnitsky; Rita Bardenstein; Sorel Goland; Orly Hammer Muntz; Shiri Navon Venezia; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Considerations when using discriminant function analysis of antimicrobial resistance profiles to identify sources of fecal contamination of surface water in Michigan.

Authors:  John B Kaneene; RoseAnn Miller; Raida Sayah; Yvette J Johnson; Dennis Gilliland; Joseph C Gardiner
Journal:  Appl Environ Microbiol       Date:  2007-03-02       Impact factor: 4.792

3.  Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance.

Authors:  Carlos Bantar; Eduardo Vesco; Claudia Heft; Francisco Salamone; Marcelo Krayeski; Hernán Gomez; María Alicia Coassolo; Alejandro Fiorillo; Diego Franco; Carina Arango; Fernando Duret; María Eugenia Oliva
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

4.  Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes.

Authors:  M Melzer; R Toner; S Lacey; E Bettany; G Rait
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 5.  Revolutionising bacteriology to improve treatment outcomes and antibiotic stewardship.

Authors:  David M Livermore; John Wain
Journal:  Infect Chemother       Date:  2013-03-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.